Benzinga - During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Here's a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga's Analyst Stock Ratings.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
Gilead Sciences, Inc. (NASDAQ: GILD)
- Dividend Yield: 3.80%
- RBC Capital analyst Brian Abrahams maintained a Sector Perform rating and cut the price target from $87 to $86 on March 6, 2023. This analyst has an accuracy rate of 77%.
- SVB Leerink analyst David Risinger maintained a Market Perform rating and increased the price target from $81 to $91 on Feb. 3, 2023. This analyst has an accuracy rate of 74%.
- Recent News: Kite, a Gilead Sciences company, announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel).
- Dividend Yield: 3.77%
- SVB Leerink analyst David Risinger maintained a Market Perform rating and cut the price target from $282 to $267 on Feb. 2, 2023. This analyst has an accuracy rate of 74%.
- Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and lowered the price target from $285 to $275 on Feb. 1, 2023. This analyst has an accuracy rate of 69%.
- Recent News: Amgen reported Q4 financial results and issued FY23 revenue guidance below estimates.
- Dividend Yield: 3.49%
- Wells Fargo analyst Larry Biegeisen maintained an Equal-Weight rating and cut the price target from $82 to $77 on Nov. 30, 2022. This analyst has an accuracy rate of 78%.
- Barclays analyst Matt Miksic maintained an Equal-Weight rating and slashed the price target from $90 to $85 on Nov. 25, 2022. This analyst has an accuracy rate of 71%.
- Recent News: Medtronic posted Q3 sales of $7.73 billion flat Y/Y on a reported basis and increased 4.1% organically, which exceeded the consensus of $7.53 billion.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.